Inventiva (NASDAQ:IVA) Shares Gap Down – Time to Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $4.09, but opened at $3.87. Inventiva shares last traded at $4.09, with a volume of 461,113 shares.

Analyst Upgrades and Downgrades

IVA has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Truist Financial assumed coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $16.56.

Inventiva Trading Down 1.2%

The company has a 50 day moving average of $5.40 and a 200-day moving average of $5.40.

Inventiva (NASDAQ:IVA) last released its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter. Analysts forecast that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Trading of Inventiva

A number of large investors have recently modified their holdings of IVA. Paradigm Biocapital Advisors LP acquired a new stake in Inventiva in the 4th quarter valued at about $18,600,000. ADAR1 Capital Management LLC acquired a new position in shares of Inventiva during the fourth quarter worth about $12,601,000. UBS Group AG increased its stake in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares during the period. SymBiosis Capital Partners LLC acquired a new stake in Inventiva in the fourth quarter valued at approximately $12,090,000. Finally, Millennium Management LLC raised its holdings in Inventiva by 2,267.7% in the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after acquiring an additional 2,540,540 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.